The recent LN discussions on Domperidone and Trivisol made me notice this
abstract from Medscape this week. I thought it might be of interest to
others:

The Political Economy of FDA Drug Review: Processing, Politics and
Lessons for Policy
Posted 01/07/2004

Daniel P. Carpenter

Abstract and Introduction
Abstract
U.S. Food and Drug Administration (FDA) drug review bears a structural
similarity to many decisions made by other regulatory agencies: high
uncertainty, low reversibility, avoidance of observable error, and high
political stakes that induce lobbying by interested parties. This paper
explores the policy lessons to be learned from viewing FDA drug review as
a politically shaped exercise in information processing. I argue that the
incentives facing regulators induce limits on the degree to which drug
review can be accelerated, that the same incentives could render
privatization initiatives problematic, and that political pressures could
play a useful role in identifying priority drugs.>

Jean
************
K. Jean Cotterman RNC, IBCLC
Dayton, Ohio USA

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html